Acasă › Mielom multiplu › Illinois › Chicago
Studii clinice pentru Mielom multiplu în Chicago, IL
22 studii pentru Mielom multiplu caută participanți în și în jurul orașului Chicago (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
În curs de recrutareFaza 1
- University of Chicago Medical Center /ID# 278863, Chicago
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
În curs de recrutareFaza 3
- Research Site, Chicago
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
În curs de recrutareFaza 1/2
- University of Chicago Medical Center, Chicago
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 3
- Rush University System for Health, Chicago
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
În curs de recrutareFaza 3
- University Of Illinois Medical Center, Chicago
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
În curs de recrutareFaza 4
- Northwestern University, Chicago
- University of Chicago, Chicago
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
În curs de recrutareFaza 2
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
În curs de recrutareFaza 2
- Cancer Treatment Centers of America-Chicago, Chicago
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 2
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
În curs de recrutareFaza 2
- University of Illinois at Chicago, Chicago
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
În curs de recrutareFaza 3
- Endeavor Health - Swedish Hospital, Chicago
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
În curs de recrutareFaza 3
- Advocate Illinois Masonic Medical Center, Chicago
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
În curs de recrutareFaza 1/2
- Research Site, Chicago
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
În curs de recrutareFaza 3
- Research Site, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
În curs de recrutare
- Northwestern University Feinberg School of Medicine, Chicago
Personalized Autologous Transplant for Multiple Myeloma
În curs de recrutareFaza 1
- University Illinois Chicago, Chicago
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
În curs de recrutareFaza 3
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
În curs de recrutareFaza 1
- University of Chicago, Chicago
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
În curs de recrutareFaza 1
- University of Chicago Medical Center, Chicago
Hypofractionation (Radiation) Trial for Multiple Myeloma
În curs de recrutareFaza 1
- The University of Chicago Comprehensive Cancer Center, Chicago
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
În curs de recrutareFaza 1/2
- Northwestern, Chicago
Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
În curs de recrutareFaza 1
- University of Illinois Cancer Center, Chicago
Studii pentru Mielom multiplu în alte orașe
- New York City, NY60 studii
- Boston, MA42 studii
- Atlanta, GA41 studii
- Houston, TX38 studii
- Durham, NC37 studii
- Nashville, TN32 studii
- Denver, CO27 studii
- Rochester, MN24 studii
- St. Louis, MO24 studii
- Columbus, OH24 studii
- Baldwin Park, CA23 studii
- Seattle, WA22 studii
Alte studii în Chicago
- Cancer pulmonar cu celule non-pătrate61 studii
- Cancer de sân58 studii
- Cancer (toate tipurile)51 studii
- Cancer metastatic45 studii
- Cancer de prostată45 studii
- Obezitate41 studii
- Cancer pulmonar41 studii
- Cancer ovarian36 studii
- Accident vascular cerebral34 studii
- Cancer colorectal33 studii
- Insuficiență cardiacă31 studii
- Supraponderalitate28 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.